TBIO
$6.29
Translate Bio
$.30
5.01%
TBIO
Earnings Whisper ®
N/A
3rd Quarter September 2018
Consensus:  ($0.04)
Revenue:  $22.50 Mil
Thursday
Nov 22
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TBIO reports earnings?
Beat
Meet
Miss

Where is TBIO's stock price going from here?
Up
Flat
Down
Stock chart of TBIO
Analysts
Summary of analysts' recommendations for TBIO
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variations in the human genetic code. The company believes its WAVE System, which incorporates its proprietary DNASep separation column and associated software, chemical reagents and other consumable items, will become a leading tool to analyze genetic mutations. The WAVE System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other techniques.
Peers
IlluminaPerkinElmerAgilent TechnologiesCoherentBio-Rad LaboratoriesHarvard Bioscience